Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas